Nanobiotix S.A. (EPA:NANO)
France · Delayed Price · Currency is EUR 22.86
-2.54 (-10.00%)
Oct 2, 2026, 5:35 PM CET
Nanobiotix Revenue
Nanobiotix had revenue of 5.55M EUR in the half year ending June 30, 2026, a decrease of -40.24%. This brings the company's revenue in the last twelve months to 11.51M, up 13.26% year-over-year. In the year 2025, Nanobiotix had annual revenue of 32.59M.
Revenue (ttm)
11.51M
Revenue Growth
+13.26%
P/S Ratio
112.17
Revenue / Employee
115.06K
Employees
100
Market Cap
1.29B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.59M | 39.78M | - |
| Dec 31, 2024 | -7.19M | -43.40M | - |
| Dec 31, 2023 | 36.21M | 31.43M | 658.12% |
| Dec 31, 2022 | 4.78M | 2.13M | 80.43% |
| Dec 31, 2021 | 2.65M | 135.00K | 5.37% |
| Dec 31, 2020 | 2.51M | -29.00K | -1.14% |
| Dec 31, 2019 | 2.54M | -938.00K | -26.96% |
| Dec 31, 2018 | 3.48M | -242.53K | -6.52% |
| Dec 31, 2017 | 3.72M | -1.70M | -31.36% |
| Dec 31, 2016 | 5.42M | 1.41M | 35.03% |
| Dec 31, 2015 | 4.02M | 1.24M | 44.91% |
| Dec 31, 2014 | 2.77M | 2.59M | 1,398.23% |
| Dec 31, 2013 | 184.94K | -785.67K | -80.95% |
| Dec 31, 2012 | 970.61K | -389.71K | -28.65% |
| Dec 31, 2011 | 1.36M | 225.46K | 19.87% |
| Dec 31, 2010 | 1.13M | -1.63M | -59.00% |
| Dec 31, 2009 | 2.77M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 142.94M |
| Genfit | 60.21M |
| Cellectis | 55.86M |
| MedinCell | 24.28M |
| Innate Pharma | 9.81M |
| Sensorion | 6.16M |
| Transgene | 5.62M |
| ABIVAX Société Anonyme | 4.67M |
Nanobiotix News
- 17 hours ago - Nanobiotix Names Arnd Christ CFO As Rhijn Steps Down - Nasdaq
- 1 day ago - Nanobiotix (NBTX) Names Arnd Christ as CFO Amid Share Price Drop - GuruFocus
- 1 day ago - Nanobiotix appoints Arnd Christ CFO - TheFly
- 1 day ago - NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer - GlobeNewsWire
- 3 days ago - Nanobiotix S.A. (NBTX) Earnings Review: Clinical Progress Meets a Cash-Runway Test - AlphaStreet
- 8 days ago - Nanobiotix (NBTX) Faces High Price-to-Sales Valuation Amid Continued Losses - GuruFocus
- 8 days ago - NANOBIOTIX Provides First Half 2026 Operational and Financial Update - GlobeNewsWire
- 8 days ago - Nanobiotix Earnings release: H1 2026 - Filings